Skip to main content

Maria Cristina Díaz de Heredia Rubio

I am a pediatrician specialized in pediatric hematology and oncology and in hematopoietic stem cell transplantation. My clinical and research activity focuses on blood disorders, leukemias, and other non-oncological hematological diseases, as well as on hematopoietic stem cell transplantation in children. Since 2005, I am the Head of the Pediatric Hematology Section and I lead the Hematopoietic Stem Cell Transplantation and Advanced Therapies Program within the Department of Pediatric Oncology and Hematology. I am committed to bringing the most innovative treatments to our patients. At the national level, I lead the pediatric group of the Spanish Group for Hematopoietic Transplantation (GETH) and the hematopoietic stem cell transplantation group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP), with the aim of improving the clinical outcomes of this procedure in children and adolescents. I am an active member of the board of the European pediatric hematopoietic stem cell transplantation group of the European Society for Blood and Marrow Transplantation (EBMT), and I actively participate in the SEHOP bone marrow failure working group. My commitment and dedication to hematopoietic stem cell transplantation and bone marrow failure syndromes have made me a national reference in these fields.

Institutions of which they are part

Predoctoral researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca
Head of Section
Paediatric Oncology and Haematology
Children's Hospital and Woman's Hospital
Maria Cristina Díaz de Heredia Rubio

Maria Cristina Díaz de Heredia Rubio

Maria Cristina Díaz de Heredia Rubio

Institutions of which they are part

Predoctoral researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca
Head of Section
Paediatric Oncology and Haematology
Children's Hospital and Woman's Hospital

I am a pediatrician specialized in pediatric hematology and oncology and in hematopoietic stem cell transplantation. My clinical and research activity focuses on blood disorders, leukemias, and other non-oncological hematological diseases, as well as on hematopoietic stem cell transplantation in children. Since 2005, I am the Head of the Pediatric Hematology Section and I lead the Hematopoietic Stem Cell Transplantation and Advanced Therapies Program within the Department of Pediatric Oncology and Hematology. I am committed to bringing the most innovative treatments to our patients. At the national level, I lead the pediatric group of the Spanish Group for Hematopoietic Transplantation (GETH) and the hematopoietic stem cell transplantation group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP), with the aim of improving the clinical outcomes of this procedure in children and adolescents. I am an active member of the board of the European pediatric hematopoietic stem cell transplantation group of the European Society for Blood and Marrow Transplantation (EBMT), and I actively participate in the SEHOP bone marrow failure working group. My commitment and dedication to hematopoietic stem cell transplantation and bone marrow failure syndromes have made me a national reference in these fields.

In terms of research, I am a member of the “Childhood Cancer and Blood Disorders” group at the Vall d’Hebron Research Institute (VHIR) and I lead the Hematopoietic Stem Cell Transplantation and Advanced Therapies Program within this group. I am the national coordinator of the international clinical trial ALL-SCT FORUM, with the objective to identify the optimal transplantation strategy in children and adolescents with acute lymphoblastic leukemia. In the field of advanced cellular therapies, I work on several innovative projects in gene therapy for congenital diseases, as well as on the use of mesenchymal cells and antigen-specific cytotoxic lymphocytes for the treatment of certain post-transplant complications.

Projects

Red Temática de Investigación Cooperativa en Cáncer - RTICC

IP: Josep Sánchez de Toledo Codina
Collaborators: Soledad Gallego Melcón, Luís Gros Subias, Pablo Velasco Puyó, Aroa Soriano Fernández, Maria Cristina Díaz de Heredia Rubio, Miguel Segura Ginard, Constantino Sábado Álvarez, Anna Llort Sales, Laura Alonso Garcia, Josep Roma Castanyer
Funding agency: Instituto de Salud Carlos III
Funding: 186750
Reference: RD12/0036/0016
Duration: 01/01/2013 - 30/06/2017

Ensayo clínico Fase I/II para evaluar la seguridad y eficacia de la movilización y colecta de células CD34+ tras tratamiento con plerixafor y filgrastim en pacientes con Anemia de Fanconi para su posterior uso en ensayos de terapia génica

IP: Maria Cristina Díaz de Heredia Rubio
Collaborators: Josep Sánchez de Toledo Codina, Raquel Hladun Alvaro
Funding agency: Ministerio Sanidad
Funding: 437580
Reference: EC11-559
Duration: 01/01/2012 - 30/06/2018

Estudio de la inmunidad mediada por células en el proceso diagnóstico de los pacientes pediátricos con sospecha de InmunoDeficiencia Combinada (IDC)

IP: Mónica Martínez Gallo
Collaborators: Aina Aguiló Cucurull, Maria Cristina Díaz de Heredia Rubio, Andrea Martín Nalda
Funding agency: Instituto de Salud Carlos III
Funding: 104170.11
Reference: PI11/01086
Duration: 01/01/2012 - 30/04/2015

Generación y diferenciación de células madre pluripotentes inducidas (IPS) de pacientes con enfermedades genéticas del sistema inmuno-hematopoyético

IP: Josep Sánchez de Toledo Codina
Collaborators: Soledad Gallego Melcón, Ramon Gimeno Martinez, Lluis Martorell Cedres, Maria Cristina Díaz de Heredia Rubio, Sergio López Estévez, Silvia Casacuberta Serra, Josep Roma Castanyer
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 302540
Reference: PLE2009-0100
Duration: 10/12/2009 - 31/10/2013

Ministerio de Ciencia

Related news

Vall d’Hebron participates as a reference centre in Spain for early-phase clinical trials and coordinates the national ReALLNet network, promoting research into relapsed acute lymphoblastic leukemia.

The PHOENIX project, involving 13 European institutions, will evaluate for the first time in paediatric patients the drug ibrilatazar from AbilityPharma in a phase I/II clinical trial.

The European initiative Hope4Kids will strengthen and harmonise paediatric palliative care across Europe, with the aim of ensuring comprehensive, high-quality care for all children living with life-threatening or life-limiting conditions.

Related professionals

Arturo Llobell Uriel

Arturo Llobell Uriel

Predoctoral researcher
Rheumatology
Read more
Marcos Esteve Hernández

Marcos Esteve Hernández

Gestió i Administració
Digital Transformation Directorate
Read more
Sandra Gelabert Saurí

Sandra Gelabert Saurí

Research assistant
Cardiovascular Diseases
Read more
Cristina Márquez González

Cristina Márquez González

Research technician
Stroke research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.